ORMP - NASDAQ
Oramed Pharmaceuticals Inc.
$3.65
-1.6%Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
At a Glance
Live SnapshotOramed Pharmaceuticals Inc. Profit Bridge
Profitability Analysis
Gross Margin
Thin margins leave little room for error. Cost management and pricing strategy are critical.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Exceptional profitability. The company converts a significant portion of revenue to bottom-line earnings.
Effective Tax Rate
Moderate tax rate typical for most corporations. Represents standard tax burden on profits.
Oramed Pharmaceuticals Inc. Income Statement
ORMP • NASDAQ
| Oramed Pharmaceuticals Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Aug 2021 | Aug 2020 | Aug 2019 | Aug 2018 | Aug 2017 | Aug 2016 | Aug 2015 | Aug 2014 | Aug 2013 | Aug 2012 | Aug 2011 | Aug 2010 | Aug 2009 | Aug 2008 | Aug 2007 | Aug 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
2M | 0.0 | 1.3M | 2.7M | 2.7M | 2.7M | 2.7M | 2.4M | 2.5M | 641K | 0.0 | 0.0 | 0.0 | 184.3K | 197.4K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | ||||||||||||||||||||
(2M) | (193K) | (0.0) | (0.0) | (0.0) | (90K) | (90K) | (86K) | (187K) | (490K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
13K | -193K | 1.3M | 2.7M | 2.7M | 2.6M | 2.6M | 2.4M | 2.3M | 151K | 0.0 | 0.0 | 0.0 | 184.3K | 197.4K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
OPERATING INCOME | ||||||||||||||||||||
(15.1M) | (12.8M) | (17.1M) | (43.3M) | (26.9M) | (14.5M) | (17.2M) | (16.1M) | (13M) | (10.2M) | (7.4M) | (5.9M) | (4.3M) | (2.9M) | (2.4M) | (3M) | (2.8M) | (2.7M) | (3.1M) | (412.9K) | |
(8.7M) | (6.5M) | (8.1M) | (15.7M) | (5.9M) | (4.2M) | (3.7M) | (4.1M) | (2.8M) | (2.5M) | (2.6M) | (2.6M) | (2M) | (1.2M) | (1.3M) | (1.5M) | (1.3M) | (1.5M) | (918K) | (215.1K) | |
(6.4M) | (6.3M) | (9M) | (27.6M) | (21M) | (10.2M) | (13.5M) | (12M) | (10.3M) | (7.7M) | (4.8M) | (3.3M) | (2.3M) | (1.7M) | (1.2M) | (1.5M) | (1.5M) | (1.2M) | (2.2M) | (197.7K) | |
-15.1M | -12.8M | -15.8M | -40.6M | -24.2M | -11.8M | -14.6M | -13.5M | -10.8M | -10M | -7.4M | -5.9M | -4.3M | 2.9M | -2.4M | -3M | -2.8M | -2.7M | -3.1M | -412.9K | |
PRE-TAX INCOME | ||||||||||||||||||||
(0.0) | (853K) | (3.6M) | (0.0) | (6K) | (0.0) | (0.0) | (6K) | (6K) | (11K) | (0.0) | (11K) | (313.4K) | (199.1K) | (18.8K) | (14.5K) | (17.6K) | (10.3K) | (3.2M) | (3.7K) | |
2.4M | -853K | 4.4M | 3.6M | 341K | 690K | 1.1M | 897K | 779K | 463K | 168K | 214K | -294.7K | -186K | 14.5K | 10.1K | 21K | -93.5K | -3.2M | -1.7K | |
90.4M | -3.1M | 20.9M | 2.9M | 893K | -438K | -450K | -30K | -10K | -17K | -3K | 214K | -164.7K | -184.3K | 835.6K | 10.1K | 21K | 5.3M | -104K | -1.7K | |
75.3M | -15.9M | 5.1M | -37.7M | -23M | -11.5M | -14.1M | -12.7M | -10.1M | -9.6M | -7.2M | -5.7M | -4.4M | -3.3M | -1.6M | -3M | -2.8M | 2.6M | -3.2M | -414.6K | |
NET INCOME | ||||||||||||||||||||
(11.3M) | (3.2M) | (0.0) | (100K) | -2.9M | (192K) | (300K) | -800K | (400K) | (1.3M) | -1K | (4K) | -205.1K | (90.2K) | -24K | (15K) | -2.6K | (162.2K) | (3.2M) | (414.6K) | |
64.1M | -19.1M | 5.5M | -37.8M | -22.2M | -11.5M | -14.4M | -12.7M | -10.5M | -11M | -7.2M | -5.7M | -4.2M | -3.3M | -1.6M | -3M | -2.8M | -2.8M | -3.2M | -414.6K |
SEC Filings
ORMP - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 19, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 31, 2026 | March 25, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 20, 2026 | February 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 14, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 07, 2026 | January 07, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 31, 2025 | December 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 31, 2025 | December 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 17, 2025 | November 16, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 17, 2025 | November 17, 2025 | 2025 |
Related Guides
Continue your ORMP research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.